Unidad de Enfermedades Infecciosas y Microbiología del Hospital Universitario de Valme (Sevilla)
Our group consists of health care professionals (physicians, pharmacist and nurses) along with basic scientists working on aspects of HIV infection and HCV infection. Our main ongoing research lines are the following:
- Epidemiology of HCV infection, now particularly dedicated to screening programs, acute HCV infection and reinfection;
- Natural history of HIV/HCV coinfection and HCV coinfection, now focused on the risk of hepatocellular carcinoma and clinical events after HCV clearance;
- Treatment of HCV infection, including linkage to care strategies and elimination strategies in high prevalence groups, as HIV-infected patients;
- Resistance and susceptibility to HCV infection;
- Steatosis and steatohepatitis in HIV infection, from diagnosis to treatment add prevention.
As a consequence of these research lines, our group has published 164 papers during the past 10 years, reaching an H index of 25, which corresponds to an average of 15 citations per paper and a global impact factor greater than 800. In the past five years, our group obtained public competitive funding for 9 projects, including a EU project funded by 3rd Health Programme Call. The results of our studies are cited in clinical practice guidelines for HIV treatment (DHHS, BHIVA, GeSIDA), for the management of HCV infection (GEHEP, AEEH, GeSIDA, SAEI) and international clinical decision support resources as Up to Date.
In the diagnostic area, the group led by Dr. Pineda has pioneered the use of biomarkers to measure hepatic injury as a non-invasive alternative to liver biopsy. His group has also pioneered the implantation of transient hepatic elastography as a test to diagnose fibrosis, deriving from it also prognostic possibilities beyond fibrosis.
Currently, the group is involved in a European project that seeks to generate a new model of care for HCV infection in Europe.